Vanda Pharmaceuticals Inc. (VNDA) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-12
How it makes money
It earns by selling specialty pharmaceutical drugs to patients who pay via insurance or out-of-pocket, with prescription volume driving its total revenue results.
The company commercializes a portfolio of therapies for conditions such as schizophrenia, sleep disorders, and multiple sclerosis. Revenue is primarily generated through net product sales, which are highly sensitive to the number of prescriptions written by healthcare providers and the adoption rate of new patient starts.
What protects it: the moat
It relies on regulatory exclusivity and patent protections to shield its drugs from competitors, though these defenses have proven porous for key products.
The company relies on intellectual property rights to maintain market share. However, management admits that it has already suffered adverse court rulings that allowed generic versions of its sleep medication to enter the market, directly challenging its ability to sustain premium pricing and volume.
What growth costs
It must heavily reinvest in clinical trials, regulatory approvals, and aggressive marketing campaigns to keep its products competitive and reach new customers.
The company directs significant capital toward developing new indications for existing drugs and launching new products. Additionally, it funds extensive direct-to-consumer advertising and commercial infrastructure to maintain visibility in crowded therapeutic markets.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.